Combined Determination of CXCR1, CXCR2, Hyaluronic Acid and CYFRA 21-1 Receptors in the Blood in the Diagnosis of Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) occupies a large part in the structure of lung cancer incidence. NSCLC is a heterogeneous disease and includes two main histological subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SCC). Currently, there are no specific biomarkers that allow one to judge with sufficient accuracy the extent of the tumor in this disease. The results of the study indicate that the location density (MFI) of CXCR1 in granulocytes, the proportion of lymphocytes supplied with CXCR2, the level of hyaluronic acid (HA) and CYFRA 21-1 in the blood of patients with AC and SCC are significantly higher than in healthy people, already at I stages of these diseases and show further growth in subsequent stages. Diagnostic parameters for determining their level in the blood of patients with AC and SCC were higher than when measuring the "classical" tumor-associated antigen CYFRA 21-1. In order to further improve the diagnostic parameters of individual indicators, a multivariate (regression) analysis was carried out. During the analysis, 6 regression equations were created. The first includes MFI CXCR1 in granulocytes and the level of HA in the blood and makes it possible to distinguish patients with stages I and II of AC from healthy people (efficiency - 92.4%). The second includes MFI CXCR1 in granulocytes, the proportion of lymphocytes equipped with CXCR2, and the concentration of CYFRA 21-1 in the blood and allows to distinguish patients with stages I and II of AC from stages III and IV (efficiency - 92.0%). The third equation includes MFI CXCR1 in granulocytes, the proportion of lymphocytes equipped with CXCR2, and the level of HA in the blood and allows you to distinguish stage I from AK II (efficiency - 96.1%). The fourth includes the proportion of lymphocytes carrying CXCR2 and the level of HA in the blood serum to distinguish patients with stages I and II SCC from healthy people (efficiency - 92.7%). The fifth includes the proportion of lymphocytes equipped with CXCR2 and the level of HA in the blood and allows you to distinguish patients with I and II from III and IV stages of SCC (efficiency - 90.4%). The sixth equation includes the proportion of lymphocytes carrying CXCR2 and the level of HA in the blood and can be used to distinguish stage I from stage II SCC with 93.1% efficiency.